High-throughput screening market set to be worth $26.4bn by 2025
According to a new report, the high-throughput screening market will increase at a CAGR of 11.5 percent from 2020 to 2025.
List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
According to a new report, the high-throughput screening market will increase at a CAGR of 11.5 percent from 2020 to 2025.
With the right solution organisations can simplify their lab-based working, while ensuring the highest level of compliance with regulatory requirements.
Researchers have developed a workflow to study the behaviour of C. elegans in a high-throughput screen to identify Parkinson's disease drugs.
Phenotypic profiling identifies biomarkers and mechanisms of toxicity.
Vascor (bepridil) could be used to treat COVID-19, according to a new study which screened drugs to repurpose against SARS-CoV-2.
A high-throughput screening assay for macrocyclic peptides with affinity to ubiquitin has been created by researchers.
A team has developed a machine learning approach to screen for and identify drugs that could be repurposed against COVID-19 in the elderly.
In this ebook, we’ll see how digitally enabling your organisation can increase capacity and improve vaccine production.
Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.
This whitepaper describes the automated culturing of hiPSC-derived cells for high-throughput phenotypic screening, using validated phenotypic assays.
In this whitepaper we explore some of the major bottlenecks in the development lifecycle and the current barriers to effective digital transformation.
28 January 2021 | By Eurofins DiscoverX & Sanford Burnham Prebys Discovery
In this on-demand webinar industry experts discuss how the InCELL Pulse technology provides a valuable tool for the discovery and characterisation of novel SHP2 inhibitors.
Learn how Simple Western automated immunoassays screen degraders and IMiD compounds to quantify degradation activity, providing accurate DC50 and Dmax values.
A team has developed a new way to discover peptide therapeutics that inhibit HDAC enzymes and are effective against cancer.
Identifying allosteric modulators and biased agonists for clinically relevant GPCRs. Case Studies using Eurofins Discovery’s GPCR product solutions.